Trials / Completed
CompletedNCT02706795
Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Revance Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, dose-escalation study to assess the safety and preliminary efficacy of daxibotulinumtoxinA in subjects with isolated cervical dystonia (CD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DaxibotulinumtoxinA | Low, mid, and high dose sequential treatments of daxibotulinumtoxinA in dose-escalation safety and efficacy study |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2016-12-07
- Completion
- 2017-07-17
- First posted
- 2016-03-11
- Last updated
- 2019-11-06
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02706795. Inclusion in this directory is not an endorsement.